Cargando…
Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments
BACKGROUND: The COVID-19 pandemic has presented unique challenges for rapidly designing, initiating, and delivering therapeutic clinical trials. PRINCIPLE (Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses) is the UK national platform investigating repurpos...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771189/ https://www.ncbi.nlm.nih.gov/pubmed/35057841 http://dx.doi.org/10.1186/s13063-021-05965-4 |
_version_ | 1784635545542983680 |
---|---|
author | Cake, Caroline Ogburn, Emma Pinches, Heather Coleman, Garry Seymour, David Woodard, Fran Manohar, Sinduja Monsur, Marjia Landray, Martin Dalton, Gaynor Morris, Andrew D. Chinnery, Patrick F. Hobbs, F. D. Richard Butler, Christopher |
author_facet | Cake, Caroline Ogburn, Emma Pinches, Heather Coleman, Garry Seymour, David Woodard, Fran Manohar, Sinduja Monsur, Marjia Landray, Martin Dalton, Gaynor Morris, Andrew D. Chinnery, Patrick F. Hobbs, F. D. Richard Butler, Christopher |
author_sort | Cake, Caroline |
collection | PubMed |
description | BACKGROUND: The COVID-19 pandemic has presented unique challenges for rapidly designing, initiating, and delivering therapeutic clinical trials. PRINCIPLE (Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses) is the UK national platform investigating repurposed therapies for COVID-19 treatment of older people in the community at high risk of complications. Standard methods of patient recruitment were failing to meet the required pace and scale of enrolment. This paper describes the development and appraisal of a near real-time, data-driven, ethical approach for enhancing recruitment in community care by contacting people with a recent COVID-19 positive test result from the central NHS Test and Trace service within approximately 24–48 h of their test result. METHODS: A multi-disciplinary team was formed to solve the technical, ethical, public perception, logistical and information governance issues required to provide a near-real time (approximately within 24–48 h of receiving a positive test) feed of potential trial participants from test result data to the research team. PRINCIPLE was also given unique access to the Summary Care Record (SCR) to ensure safe prescribing, and to enable the trial team to quickly and safely bring consented patients into the trial. A survey of the public was used to understand public perceptions of the use of test data for this proposed methodology. RESULTS: Prior to establishing the data service, PRINCIPLE registered on average 87 participants per week. This increased by up to 87 additional people registered per week from the test data, contributing to an increase from 1013 recruits to PRINCIPLE at the start of October 2020 to 2802 recruits by 20 December 2020. Whilst procedural caveats were identified by the public consultation, out of 2639 people contacted by PRINCIPLE following a positive test result, no one raised a concern about being approached. CONCLUSIONS: This paper describes a novel approach to using near-real time NHS operational data to recruit community-based patients within a few days of presentation with acute illness. This approach increased recruitment and reduced time between positive test and randomisation, allowing more rapid evaluation of treatments and increased safety for participants. End-to-end public and patient involvement in the design of the approach provided evidence to inform information governance decisions. TRIAL REGISTRATION: PRINCIPLE is funded by UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research. EudraCT number: 2020-001209-22. 26/03/2020 ISRCTN registry: ISRCTN86534580. 20/03/2020 REC number: 20/SC/058 IRAS number: 281958 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05965-4. |
format | Online Article Text |
id | pubmed-8771189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87711892022-01-20 Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments Cake, Caroline Ogburn, Emma Pinches, Heather Coleman, Garry Seymour, David Woodard, Fran Manohar, Sinduja Monsur, Marjia Landray, Martin Dalton, Gaynor Morris, Andrew D. Chinnery, Patrick F. Hobbs, F. D. Richard Butler, Christopher Trials Methodology BACKGROUND: The COVID-19 pandemic has presented unique challenges for rapidly designing, initiating, and delivering therapeutic clinical trials. PRINCIPLE (Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses) is the UK national platform investigating repurposed therapies for COVID-19 treatment of older people in the community at high risk of complications. Standard methods of patient recruitment were failing to meet the required pace and scale of enrolment. This paper describes the development and appraisal of a near real-time, data-driven, ethical approach for enhancing recruitment in community care by contacting people with a recent COVID-19 positive test result from the central NHS Test and Trace service within approximately 24–48 h of their test result. METHODS: A multi-disciplinary team was formed to solve the technical, ethical, public perception, logistical and information governance issues required to provide a near-real time (approximately within 24–48 h of receiving a positive test) feed of potential trial participants from test result data to the research team. PRINCIPLE was also given unique access to the Summary Care Record (SCR) to ensure safe prescribing, and to enable the trial team to quickly and safely bring consented patients into the trial. A survey of the public was used to understand public perceptions of the use of test data for this proposed methodology. RESULTS: Prior to establishing the data service, PRINCIPLE registered on average 87 participants per week. This increased by up to 87 additional people registered per week from the test data, contributing to an increase from 1013 recruits to PRINCIPLE at the start of October 2020 to 2802 recruits by 20 December 2020. Whilst procedural caveats were identified by the public consultation, out of 2639 people contacted by PRINCIPLE following a positive test result, no one raised a concern about being approached. CONCLUSIONS: This paper describes a novel approach to using near-real time NHS operational data to recruit community-based patients within a few days of presentation with acute illness. This approach increased recruitment and reduced time between positive test and randomisation, allowing more rapid evaluation of treatments and increased safety for participants. End-to-end public and patient involvement in the design of the approach provided evidence to inform information governance decisions. TRIAL REGISTRATION: PRINCIPLE is funded by UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research. EudraCT number: 2020-001209-22. 26/03/2020 ISRCTN registry: ISRCTN86534580. 20/03/2020 REC number: 20/SC/058 IRAS number: 281958 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-021-05965-4. BioMed Central 2022-01-20 /pmc/articles/PMC8771189/ /pubmed/35057841 http://dx.doi.org/10.1186/s13063-021-05965-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Methodology Cake, Caroline Ogburn, Emma Pinches, Heather Coleman, Garry Seymour, David Woodard, Fran Manohar, Sinduja Monsur, Marjia Landray, Martin Dalton, Gaynor Morris, Andrew D. Chinnery, Patrick F. Hobbs, F. D. Richard Butler, Christopher Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments |
title | Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments |
title_full | Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments |
title_fullStr | Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments |
title_full_unstemmed | Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments |
title_short | Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments |
title_sort | development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of covid-19 community treatments |
topic | Methodology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771189/ https://www.ncbi.nlm.nih.gov/pubmed/35057841 http://dx.doi.org/10.1186/s13063-021-05965-4 |
work_keys_str_mv | AT cakecaroline developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT ogburnemma developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT pinchesheather developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT colemangarry developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT seymourdavid developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT woodardfran developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT manoharsinduja developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT monsurmarjia developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT landraymartin developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT daltongaynor developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT morrisandrewd developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT chinnerypatrickf developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT hobbsfdrichard developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments AT butlerchristopher developmentandevaluationofrapiddataenabledaccesstoroutineclinicalinformationtoenhanceearlyrecruitmenttothenationalclinicalplatformtrialofcovid19communitytreatments |